



| | Method | Specification | Result |
|--|--|------------------------------|---------------|
| Microbiological purity | Ph. Eur (current ed.) 5.1.4. | | |
| <i>Total aerobic microbial count (TAMC)</i> | 5.1.4.-1. | $\leq 10^2$ cfu/gram | < 10 cfu/gram |
| <i>Total yeast and moulds count (TYMC)</i> | 5.1.4.-1. | ≤ 10 cfu/gram | < 10 cfu/gram |
| <i>P. aeruginosa, S.aureus and Bile tolerant gram neg bacteria</i> | 5.1.4.-1. | absent | conform |
| Absence of aflatoxines | Ph.Eur (current ed.) "Determination of aflatoxins B ₁ , B ₂ , G ₁ and G ₂ in herbal drugs" (2.8.18) | < 4 µg/kg | < 2.2 µg/kg |
| Absence of pesticides | monograph | Ph. Eur (current ed.) 2.8.13 | conform |
| Absence of heavy metals | | | |
| <i>lead</i> | Ph. Eur (current ed.) | max. 20.0 ppm | 0.9 ppm |
| <i>mercury</i> | "Heavy metals in herbal drugs and fatty oils" (monograph) | max. 0.5 ppm | < 0.1 ppm |
| <i>cadmium</i> | | max. 0.5 ppm | < 0.1 ppm |
| Loss on drying | Ph. Eur (current ed.) "Loss on drying" meth. C (2.2.32) | ≤ 10.0 % | 8.2 % |
| Assay (UPLC) | | | |
| <i>fingerprint</i> | monograph | similar | conform |
| <i>dronabinol (THC)</i> | monograph | approx. 6.3 % | 6.2 % |
| <i>cannabidiol (CBD)</i> | monograph | approx. 8 % | 8.1 % |
| Related substances (UPLC) | | | |
| <i>cannabinol (CBN)</i> | monograph | < 1.0 % | 0.1 % |
| Content of container | BMC-SWV 320 | approx. 5 gram | ± 5.09 gram |
| Expiry date | | | 08 / 2018 |

I hereby certify that the above information is authentic and accurate. This batch of product has been cultivated and manufactured, including packaging and quality control at the above mentioned sites in full compliance with the GAP requirements as published in the Dutch State Gazette (Staatscourant) as the annex to the Regulation of the Minister of Health, Welfare and Sport of 9 January 2003, GMT/BMC 2340685, and with the specifications as stated in this document. The batch processing, packaging and analysis records were reviewed and found to be in compliance with GAP and GMP.

The Hague, the Netherlands, 27 September 2017

Dr. M.J. van de Velde

Head, Office of Medicinal Cannabis

Dr. M.J. van de Velde